So-young International and Jinbo have jointly released 'Miracle Collagen' ViyiMe ColPact, after five years of intensive efforts to build the strongest supply chain in medical aesthetics

On April 22, So-young International and Jinbo Biotech jointly held the 'Youth Miracle' strategic release conference. Both parties officially announced a strategic partnership – Jinbo Biotech will exclusively supply its new product ViyiMe ColPact to So-young Youth Clinics, which will formally launch 'Miracle Collagen' based on this product – an all-scenario anti-aging solution using recombinant collagen for both facial and scalp applications.

ViyiMe ColPact, as the 20th proprietary product within So-young’s 'GREEN LABEL' system, represents the synergistic implementation of both parties in the field of regenerative medical aesthetics. It also marks the entry of So-young's five-year supply chain strategy into a phase of scaled realization.

Collagen enters a period of concentrated growth, with recombinant collagen becoming the core growth driver of the industry

By 2026, the medical aesthetics industry is entering a concentrated release cycle for collagen products. On the supply side, faster regulatory approvals are driving rapid expansion of compliant products.

As of April 2026, the number of registered certificates for collagen-based Class III medical devices in the domestic market has reached 18, continuously improving the industry's supply landscape. In the market, collagen has become the third-largest segment in China’s medical aesthetics injection field. According to Forward Industry Research Institute data, in 2024, the market size of collagen injections in China's medical aesthetics sector was approximately 6.7 billion yuan, with a compound annual growth rate of 21.9% from 2021 to 2024. Structurally, recombinant collagen has emerged as the core growth driver, with its market share increasing by over 376% in ten years and reaching a penetration rate of 56.9% in 2025, gradually replacing traditional animal-derived collagen as the mainstream.

Behind this shift lies a change in consumer logic within the medical aesthetics space. Compared to shape adjustments centered on 'filling,' users are increasingly focusing on 'natural restoration,' 'tissue regeneration,' and long-term results, making regenerative projects a dominant trend and providing a market foundation for the large-scale adoption of recombinant collagen.

So-Young International collaborates with Jinbo Biotech to launch 'Miracle Collagen,' offering comprehensive anti-aging solutions

Jin Xing, Chairman and CEO of So-Young International, stated, 'Medical aesthetics consumption is undergoing a structural transformation, with industry keywords shifting from 'change' to 'restoration.' In 2025, interactions with content related to the 'natural look' on So-Young's platform were three times higher than three years ago, reflecting consumers’ growing preference for natural anti-aging effects rather than mere filling. Additionally, anti-aging demands have expanded from facial treatments to full-body refined care, with searches for 'scalp care' and 'hair volume management' increasing by over 50% annually on the platform.'

In line with the trend toward refined and full-body anti-aging consumption, So-Young International has formed a strategic partnership with Jinbo Biotech to introduce the recombinant collagen product WeiYiMei ColPact and implement four types of collagen-based anti-aging solutions for the head and face.

Moving beyond the traditional 'brand + channel' cooperation model, So-Young International and Jinbo Biotech have adopted a joint development approach that fosters mutual empowerment through industrial collaboration. Jinbo Biotech leverages its research and development capabilities and scaled production of recombinant Type III humanized collagen to provide core materials and technical support, while So-Young utilizes its user data, doctor networks, and clinical treatment experience to deeply participate in product definition, clinical solution design, and market implementation.

The newly launched WeiYiMei ColPact and its series achieve 100% alignment between the functional regions of Type III collagen and the human sequence, containing no animal-derived components and posing no risk of immune rejection. The product delivers long-term anti-aging effects through cell adhesion and tissue repair.

Targeting different skin types, age groups, and anti-aging needs, the two parties have developed four solutions: facial collagen infusion, precise wrinkle reduction with collagen, collagen ligament nourishment, and scalp collagen infusion. These form the 'Miracle Collagen Family' product portfolio, including WeiYiMei ColPact, ColNet, WeaveCol, and other products, which address fine lines, facial contours, and other issues in layers. This creates a tiered, full-scenario collagen anti-aging product lineup.

Yang Xia, Chairman of Jinbo Biotech, noted, 'China’s collagen industry stands at a historic turning point. We have achieved scaled production of direct supplementation with collagen that is 100% identical to the body’s own collagen, helping consumers restore their skin’s original state. This philosophy aligns closely with So-Young’s market perspective. By leveraging complementary industrial strengths, this collaboration represents a win-win exploration of upstream and downstream synergy and could serve as a practical reference for industry development.'

During the same period as the launch event, So-young International also introduced the 'Miracle Collagen' offline pop-up events in Beijing and Shenzhen. Through immersive displays and experiences, these events lower the barrier for users to understand new products while creating more direct communication scenarios between doctors and consumers.

Five-Year Supply Chain Layout: The 'GREEN LABEL' System Launched

The newly launched collagen product is So-young International’s 20th Green Label product. So-young Green Label products are centered on high standards, high quality, and high cost-effectiveness, covering four categories: exclusive custom products such as Plastian; self-developed products by So-young Group, such as CC Light produced by Miracle Laser; products represented by So-young Group, such as Ellansé, YouthGlow, and BBL; and products developed under commission by So-young Group, such as Silk Collagen.

The introduction of Viemei Colpact marks a key milestone in So-young International's upstream supply chain strategy that began in 2021. Over the past five years, So-young has continuously refined its supply chain layout through acquisitions, agency agreements, strategic investments, and customized development. In 2021, it acquired Miracle Laser for 790 million yuan to enter the photoelectric equipment market; in 2022, it launched the 'virtual chain' brand - So-young U+ - and secured the China distribution rights for hyaluronic acid products. From 2023 to 2025, its first self-operated light medical aesthetics clinic was established, with partnerships formed with companies like Xihong Pharma and Aotecare, covering core categories such as regenerative materials and hydrating solutions. By 2026, So-young partnered with 14 upstream manufacturers to establish the 'Youth Authentic Alliance,' further deepening industry collaboration mechanisms involving volume-price linkage, genuine product traceability, and training cooperation.

So-young International's launch of the 'GREEN LABEL' (Green Standard) product system directly addresses two major pain points in traditional medical aesthetics supply chains: price markups due to multi-level distribution and mismatches between generic products and end-user needs. The Green Label system uses compliance qualifications, full-chain traceability, and price transparency as entry criteria, dynamically selecting products based on clinical effectiveness, repurchase rates, and user feedback. By directly connecting with upstream suppliers and engaging in reverse customization, the system improves supply chain efficiency, optimizes cost structures, and aligns products more closely with consumer demands. Jin Xing, Chairman and CEO of So-young Group, stated: 'The core of light medical aesthetics chains lies in supply chains and medical delivery. The Green Label system aims to enhance cost efficiency through direct upstream connections and customized development while ensuring products better meet user needs.'

Currently, So-young Youth Clinics have expanded to 56 stores across 17 cities nationwide, with over 1.38 million cumulative treatments administered. On an industry level, competition in medical aesthetics is shifting from traffic to product and supply chain capabilities. So-young’s collaboration with Jinbo Biotech represents both a phased layout in the collagen sector and reflects a shift in roles—from connector to participant. Against the backdrop of the 'Year of Collagen,' this transition could become a significant variable influencing industry dynamics, providing a reference model for the compliant and inclusive transformation of the medical aesthetics sector.

21K Views